¹North West State Medical University named after I.I Mechnikov, St. Petersburg, Russian Federation,
²The State Pediatric Medical Academy, St. Petersburg, Russian Federation
*Corresponding author: Sergey N. Proshin, Department of pharmacology, North West State Medical University named after I.I Mechnikov. 45/5, Piskarevsky str., 195067, St. Petersburg, Russian Federation. Tel: 7- 911- 9594109. E-mail: email@example.com
Immunocytochemistry was performed on the cells taken from the ecto/endocervix and endometrium. The monoclonal antibodies produced against CD20, CD56 and TLR have been used in the immunocytochemistry. The frequency of the immunocytochemically positive cells was estimated before and after a course of sodium nucleospermate treatment, in women suffering from infertility. The real–time PCR for HPV of high oncogenic risk was also studied. After the course of the treatment, the frequency of CD20, and especially of CD56 positive cells, was found to decrease. The concomitant lowering of the HPV of high oncogenic risk quantity was determined by real–time PCR. Otherwise, the frequency of TLR4 and TLR9 positive cells was found to be elevated. The data presented here proved the assumption that sodium nucleospermate actively induces an innate immune response and eliminated factors inciting endometrial inflammation.
1. Medzhitov R, Preston–Hurlburt P, Kopp E. MyD88 is an adaptor protein in the hToll/IL–1 receptor family signaling pathways. Mol Cel 1998; 2(2): 253–58.
2. Lee J, Chuang TH, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll–like receptor 7. PNAS USA 2003; 100(11): 6646–51.
3. Herbst–Kralovetz MM, Quayle AJ, Ficarra M, et al. Quantification and comparison of Toll–like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am J Reprod Immun 2008; 59(3): 212–24.
4. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll–like receptor 3 that blocks double–stranded RNA–mediated signaling. BBRC 2002; 293(5): 1364–69.
5. Abrahams VM, Bole-Aldo P, Kim YM, et al. Divergent trophoblast responses to bacterial products mediated by Toll-like receptors. J Immunol 2004; 173: 4286–96.
6. Andersen JM, AlKhairy D, Ingalls RR. Innate immunity at the mucosal surface: role of Toll–like receptor 3 and Toll–like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biology of reproduction 2006; 74(5): 824–31.
7. Häcker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG–DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor–associated factor (TRAF) 6. J Exp Med 2000; 192(4): 595–600.
8. Hemmi H, Kaisho T, Takeuchi O, et al. Small–antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 2002; 3(2):196–200.
9. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7–mediated recognition of single–stranded RNA. Science 2004; 303(5663): 1529–31.
10. Lien E, Sellati TJ, Yoshimura A, et al. Toll–like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999; 274(47): 33419–25.
11. Kirschning CJ, Schumann RR. TLR2: cellular sensor for microbial and endogenous molecular patterns. Cur Topics in Microbiol & Immunol 2002; 270: 121–44.
12. Sen GC, Sarkar SN. Transcriptional signaling by double–stranded RNA: role of TLR3. Cytokine and Growth Factor Reviews 2005; 16(1): 1–14.
13. Jacobs BL, Langland JQ. When two strands are better than one: the mediators and modulators of the cellular responses to double–stranded RNA. Virology 1996; 219(2): 339–49.
14. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll–like receptor 3. J Biol Chem 2004; 279(13): 12542–50
15. Aksoy E, Zouain CS, Vanhoutte F, et al. Double–stranded RNAs from the helminth parasite Schistosoma activate TLR3 in dendritic cells. J Bio Chem 2005; 280(1): 277–83.
16. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A, Coutlée F, Franco EL. Human papilloma virus (HPV) types 16, 18, 31, 45 DNA loads and HPV–16 integration in persistent and transient infection in young women. BMS Infection Disease 2010; 10: 326.
17. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. Toll–like receptor (TLR) expression and TLR–mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004; 112(3): 428–36.
18. Fazeli A, Bruce C, Anumba DO. Characterization of Toll–like receptors in the female reproductive tract in humans. Hum Reprod 2005; 20(5): 1372–78.
19. Lin Z, Xu J, Jin X, Zhang X, Ge F. Modulation of expression of Toll–like receptors in the human endometrium. Am J Reprod Immun 2009; 61(5): 338–45.
20. Pioli PA, Amiel E, Schaefer TM, Connolly JE, Wira CR, Guyre PM. Differential expression of Toll–like receptors 2 and 4 in tissues of the human female reproductive tract. Infect & Immun 2004; 72(10): 5799–5806.
21. Aflatoonian R, Tuckerman E, Elliott SL, et al. Menstrual cycle–dependent changes of Toll–like receptors in endometrium. Hum Reprod 2007; 22(2): 586–93.
22. Ulevitch RJ. Immunology: Toll gates for pathogen selection. Nature 1999; 401(6755): 755–56.
23. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD–2 in LPS responsiveness and TLR4 distribution. Nature Immun 2002; 3(7): 667–72.
24. Gregg CR, Melly MA, Hellerqvist CG, Coniglio JG, McGee ZA. Toxic activity of purified lipopolysaccharide of Neisseria gonorrhoeae for human Fallopian tube mucosa. J Infect Diseases 1981; 143(3): 432–39.
25. Naumann M, Weßler S, Bartsch C, Wieland B, Meyer TF. Neisseria gonorrhoeae epithelial cell interaction leads to the activation of the transcription factors nuclear factor kB and activator protein 1 and the induction of inflammatory cytokines. J Exp Med 1997; 186(2): 247–58.
26. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll–like receptor–4 complex. J Immun 2000; 164(2): 558–61.
27. Netea MG, Van Der Graaf C, Van Der Meer JWM, Kullberg BJ. Recognition of fungal pathogens by Toll–like receptors. Europ J Clin Microbiol & Infect Diseases 2004; 23(9): 672–76.
28. Doyle SE, Vaidya SA, O’Connell R, et al. IRF3 mediates a TLR3/TLR4–specific antiviral gene program. Immunity 2002; 17(3): 251–63.
29. Hemmi H, Tekeuchi O, Kawai T, et al. A Toll–like receptors recognizes bacterial DNA. Nature 2000; 408(6813): 740–45.
30. Tabeta K, Georgel P, Janssen E, et al. Toll–like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. PNAS USA 2004; 101(10): 3516–21.
31. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through Toll–like receptor 9. Blood 2004; 103(4): 1433–37.
32. Hirata T, Osuga Y, Hamasaki K, et al. Expression of Toll–like receptors 2, 3, 4, and 9 genes in the human endometrium during the menstrual cycle. J Reprod Immunol 2007; 72(1–2): 53–60.
33. Hart KM, Murphy AJ, Barrett KT, Wira CR, Guyre PM, Pioli PA. Functional expression of pattern recognition receptors in tissues of the human female reproductive tract. J Reprod Immunol 2009; 80(1–2): 33–40.
34. Ghosh M, Schaefer TM, Fahey JV, Wright JA, Wira CR. Antiviral responses of human Fallopian tube epithelial cells to Toll–like receptor 3 agonist poly(I:C). Fertility and Sterility 2008; 89(5, supplement 1): 1497–1506.
35. Harwani SC, Lurain NS, Zariffard MR, Spear GT. Differential inhibition of human cytomegalovirus (HCMV) by Toll–like receptor ligands by interferon–beta in human foreskin fibroblasts and cervical tissue. Virology Journal 2007; 4: Article 133.
36. Askra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A. Toll–like receptor agonist synergistically increase proliferation and activation of B cells by Epstein–Barr virus. J Virology 2010; 84(7): 3612–23.
The fully formatted PDF version is available.
Int J Biomed. 2012; 2(4):261-266. © 2012 International Medical Research and Development Corporation. All rights reserved.